Akari Therapeutics Reports $4.8 Million Net Loss and Faces Liquidity Challenges in Latest Filing

Akari Therapeutics Plc reported significant financial challenges in its latest 10-Q filing for the quarter ending June 30, 2026. The company recorded a net loss of $4.8 million for the quarter, compared to a loss of $1.9 million in the same period last year. For the first half of 2026, the net loss reached $19.3 million, a substantial increase from $5.6 million in the first half of 2025. The increase in losses is attributed primarily to heightened research and development expenses, which surged to $2.1 million for the quarter and $3.5 million for the six months, reflecting a focus on advancing its lead product candidate, AKTX-101.

Total operating expenses for the second quarter of 2026 amounted to $4.6 million, up from $3.1 million in the prior year, driven by increased research and development activities and non-cash impairment charges totaling $12.1 million related to goodwill and other intangible assets. The company’s accumulated deficit as of June 30, 2026, stood at $283.8 million, with cash and restricted cash totaling $7.7 million, which is insufficient to fund operations for the next year without additional financing.

In terms of strategic developments, Akari Therapeutics has entered into a strategic research collaboration with Whitehawk Therapeutics to evaluate its proprietary PH1 spliceosome-modulating payload technology in combination with Whitehawk’s ADC platform. This collaboration aims to enhance the development of improved cancer treatments. Additionally, the company has made progress in its manufacturing capabilities, having initiated GMP manufacturing activities for AKTX-101, which is expected to enter clinical trials by mid-2027.

The company has also seen changes in its capital structure, including a significant increase in the number of outstanding shares, which rose to approximately 140 billion by the end of June 2026, up from about 90 billion at the end of 2025. This increase was primarily due to financing activities, including a private placement that generated approximately $5.2 million in net proceeds. However, Akari continues to face substantial liquidity challenges, raising concerns about its ability to continue as a going concern without securing additional funding.

Looking ahead, Akari Therapeutics acknowledges the need for substantial additional financing to support its ongoing research and development efforts. The company is exploring various funding strategies, including private placements and potential collaborations, but has not yet secured commitments for future funding. The outlook remains uncertain, with the company emphasizing the risks associated with its ability to generate revenue and achieve profitability in the future.